Evogene Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0011050551
USD
1.10
0.05 (4.27%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Evogene Ltd. stock-summary
stock-summary
Evogene Ltd.
Pharmaceuticals & Biotechnology
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.
Company Coordinates stock-summary
Company Details
13 Gad Feinstein st., Park Rehovot P.O.B 2100 REHOVOT None : 7612002
stock-summary
Tel: 972 8 9311900
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.1%)

Foreign Institutions

Held by 10 Foreign Institutions (0.23%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Martin Gerstel
Chairman of the Board
Dr. Adrian Percy
Director
Prof. Oded Shoseyov
Director
Ms. Sarit Firon
Independent Director
Mr. Ziv Kop
Independent Director
Dr. Kinneret Livnat Savitsky
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 11 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

3.10

stock-summary
Return on Equity

415.27%

stock-summary
Price to Book

-3.12